

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History'

2022 Leading Edge of Cancer Research Symposium hosted by MD Anderson



MOREHealth Research Group:

more than clinical data!




Authors: Marina Borges and Luisa Lopes-Conceição Portuguese Oncology Institute of Porto, Portugal

MOREHealth Research Group



To impact healthcare local and globally by producing knowledge in the following areas: healthcare Management, Outcomes Research, and health Economics.



To enlarge the scope of comprehensiveness in cancer care!



Impact on Healthcare

 \mathbb{R} RG based on a CCC => Strong integration with IPU's

 Small projects to solve the needs identified by healthcare professional (e.g., Early integration of palliative care in patients with advanced or metastatic lung cancer)

Value based healthcare for Outcomes In breast and lung Cancer in Europe

• Use of RWE across the medicine's lifecycle (e.g.: natural history studies, external control arms and health technology assessments);

• Participation on international project, funded by EU program, for unlock the full potential of RWD of cancer hospitals to support decision-making in oncology drugs.



Scientific Outputs Soares et al. BMC Pulmonary Medicine (2020) 20:240 https://doi.org/10.1186/s12890-020-01270-z **BMC Pulmonary Medicine** Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative Marta Soares^{1*}, Luís Antunes², Patricia Redondo¹, Marina Borges¹, Ruben Hermans⁴, Dony Patel⁴, Fiona Grimson⁴, Robin Munro⁴, Carlos Chaib⁵, Laure Lacoin⁶, Melinda Daumont⁷, John R. Penrod⁸, John C. O'Donnell⁸, Maria José Bento^{2,9} and Francisco Rocha Gonçalves³ The Broad 57 (2021) 1-4 BREAST The Breas Comparing the cost of non-metastatic breast cancer care in a lowincome vs a high-income country: A plea for an optimal allocation of National and health resources in Sub-Saharan Africa Mariana Brandão ^{4, b, c}, Samantha Morais ^{4, d}, Assucena Guisseve ^{6, f}, Genoveva Bata ^b Marina Borges ^{b, b}, Satish Tulsidás ^{4, d, g}, Susana Pereira ^{3, b}, Carla Carrilho ^{6, f}, **Internal Projects** EMDpen Healthcare use and costs in early breast cancer: a patient-level data analysis Partnerships Check for updates according to stage and breast cancer subtype Mariana Brandão 🧿 ,^{1,2,3} Samantha Morais 💿 ,^{1,4} Luísa Lopes-Conceição 🧿 ,¹ Filipa Fontes O, 1 Natália Araújo O, 1 Teresa Dias, 5 Deolinda Pereira, Marina Borges O, 2.6 Susana Pereira O, 1.7 Nuno Lunet O 1.4 International Borges et al. Health Economics Review (2021) 11:33 Health Economics Review https://doi.org/10.1186/s13561-021-00332-0 Projects RESEARCH The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data Andreia Borges^{1,2}, Filipa Pereira³, Patricia Redondo^{1,2}, Luís Antunes^{4,5}, Cláudia Vieira^{3,6,7}, Pedro Antunes⁸, Maria José Bento^{45,9}, Susana Sousa³, José Machado Lopes¹, Francisco Rocha-Gonçalves¹⁰, Joaquim Abreu de Sousa⁸, Deolinda Sousa Pereira³ and Marina Borges^{1,2*} (R) Check for update **Regular Article** Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Paola Ghione,^{1,2}* M. Lia Palomba,²* Ank R. Patel,² Sabela Bobilo,* Kevin Deighton,⁸ Caron A. Jacobson,⁴ Myma Nahas,³ Arthory J. Histswell,⁹ A. Scott. Jung,⁹ Steve Kantens, ¹Jula Thomton Snider,⁹ Sattra S. Neelapu,⁴ Maria Teresa Ribeiro,⁶ M. Alan Brochkurt,¹⁶¹ Hiven Obsequieres,¹⁷ John Radiorul, ¹and John G. Gribben⁴



Future Directions

- Improve the <u>quality of RWD/RWE</u> (e.g.: OMOP CDM,...);
- Increase the number of <u>international collaborations</u>, including the participation in projects with EU funding;
- Enhance the impact of research activities in decision-making and/or in clinical practice;
- Move towards Patient-Centered Outcomes Research.





Thank you!

marina.borges@ipoporto.min-saude.pt marinaaborges@sapo.pt